close

Log in

Access to premium content is restricted to healthcare professionals / registered members. Login with your email address to continue.

Forgot Your Password?

Don't have an account? Sign up

module menu icon

Human Papillomavirus (HPV) Part 2

Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
References and Further Reading
Quiz

module menu icon References and Further Reading

Congratulations on completing this module  (0% complete)

quiz close icon

module menu icon References and Further Reading

REFERENCES

  1. Gardasil®9 Prescribing Information for GB. Summary of Product Characteristics. Accessed Mar 2025. Available at: https://www.emcpi.com/pi/32240

  2. Overview | Community pharmacies: promoting health and wellbeing | Guidance | NICE. Accessed April 11, 2025. https://www.nice.org.uk/guidance/ng102

  1. World Health Organization. Questions and answers about HPV vaccination: Information for parents and caregivers. Accessed Mar 2025. Available at: https://cdn.who.int/media/docs/librariesprovider2/default-document-library/who-hpv-qa.pdf?sfvrsn=d0bf716b_3

  2. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. An update. Published September 2012. Accessed Mar 2025. Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf

  3. Ferris DG, Brown DR, Giuliano AR, et al. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Res. 2020 Dec;10:100202.

  1. Ingles DJ et al. Papillomavirus Res. 2015;1:126–135.

  2. Bruni L, Albero G, Rowley J, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. Lancet Glob Health. 2023 Sep;11(9):e1345-e1362.

  1. Beachler DC et al. J Infect Dis. 2016;213:1444–1454.

  2. Beachler DC et al. Cancer Epidemiol Biomarkers Prev. 2018;27:496–502.

  3. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res. 2010 Nov 1;70(21):8569-77.

  1. Ranjeva SL, Baskerville EB, Dukic V et al., Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity, Proc. Natl. Acad. Sci. U.S.A.114 (51) 13573-13578, (2017).

12.  Royal College of Physicians of Ireland. NIAC Immunisation Guidelines. Chapter 10. Human papillomavirus. Published June 6, 2023. Accessed Mar 2025. Available at: https://rcpi.access.preservica.com/uncategorized/IO_4a962f3d-d504-4c3c-aae9-968c04de60f5/

13.  WHO Global strategy to accelerate the elimination of cervical cancer as a public health problem. November 2020. Available at Global strategy to accelerate the elimination of cervical cancer as a public health problem (who.int). Last accessed: April 2025

14.  National Health Services (NHS). What is cervical screening? Accessed Mar 2025. Available at: https://www.nhs.uk/conditions/cervical-screening/what-is-cervical-screening/

15.  Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021 144:106399.

16.   Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd edition. Geneva: World Health Organization; 2014. 3, Community mobilization, education and             counselling. Accessed Mar 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK269611/

17.  Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015 Jun 15;136(12):2752-60.

18.  World Health Organization (WHO). HPV vaccine communication. Special considerations for a unique vaccine: 2016 update. Accessed Mar 2025. Available at: https://iris.who.int/bitstream/handle/10665/250279/WHO-IVB-16.02-eng.pdf?sequence=1

19.  Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in United Kingdom of Great Britain and Northern Ireland. Summary Report 10 March 2023. [Date Accessed: 10 April 2025] ICO/IARC HPV Information Centre

ADDITIONAL RESOURCES

Gardasil®9 Prescribing Information for GB. Summary of Product Characteristics. Accessed Apr 2025. Available at: https://www.emcpi.com/pi/32240

European Centre for Disease Prevention and Control. EU vaccine scheduler. Accessed Apr 2025.
Available at: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=38&SelectedCountryIdByDisease=-1

PROTECT EUROPE. Vaccinating Europe to protect against HPV cancers. Accessed Apr 2025. Available at: https://hpvhub.ipvsoc.org/protect-europe

This content has been developed and funded by Merck Sharp and Dohme (MSD).

GB-GSL-00824

Change privacy settings